Streetbeat News

BSEM

BioStem Technologies Inc

https://www.biostemtechnologies.com/

CEO

Marc Barhonovich

Industry

Medicinal and Botanical Manufacturing

Open

10.65

Mkt cap

176M

Volume

42K

High

10.92

P/E Ratio

-18.86

52-wk high

28.26

Low

9.85

Div yield

N/A

52-wk low

6.77

BioStem Technologies, Inc. has received IRB approval to advance a clinical trial for its BioREtain® technology, aimed at treating venous leg ulcers. The study will compare BioStem's amnion chorion allograft with the standard of care to demonstrate superior outcomes and support market expansion.

Portfolio Pulse from

February 24, 2025 | 12:15 pm

BioStem Technologies, Inc. has received IRB approval to advance a clinical trial for its BioREtain® technology aimed at treating venous leg ulcers. This marks a significant step in the development of their placental-derived products for advanced wound care.

Portfolio Pulse from

February 24, 2025 | 12:15 pm

BioStem Technologies reported a record preliminary fourth-quarter net revenue of $102.9 million and expects full-year 2024 net revenue to reach $301.8 million. The company focuses on placental-derived products for advanced wound care.

Portfolio Pulse from

January 13, 2025 | 12:15 pm

BioStem Technologies has initiated a clinical trial to evaluate its BioREtain® technology in treating diabetic foot ulcers using Vendaje®. This trial aims to compare Vendaje® with the standard care for non-healing diabetic foot ulcers.

Portfolio Pulse from

January 08, 2025 | 12:15 pm

BioStem Technologies has initiated a clinical trial to evaluate the effectiveness of its BioREtain® technology in treating diabetic foot ulcers using Vendaje®. The study aims to demonstrate superior wound treatment compared to the standard of care, potentially supporting market expansion.

Portfolio Pulse from

January 08, 2025 | 12:00 pm

BioStem Technologies' CEO will present at the Biotech Showcase 2025, with the presentation webcast scheduled for January 13, 2025.

Portfolio Pulse from

January 02, 2025 | 12:15 pm

BioStem Technologies' CEO, Jason Matuszewski, will present a corporate overview at the Biotech Showcase 2025 in San Francisco. The company focuses on placental-derived products for advanced wound care.

Portfolio Pulse from

January 02, 2025 | 12:15 pm

Kane Biotech has announced a change in its US distribution partner for its revyve™ Antimicrobial Wound Gel. BioStem Technologies has signed a letter of intent to acquire exclusive US distribution rights for revyve™ from ProgenaCare Global.

Portfolio Pulse from

November 27, 2024 | 1:45 pm

BioStem Technologies Inc. has signed a Letter of Intent to acquire wound care products and technologies from ProgenaCare Global. This acquisition aims to enhance BioStem's portfolio in the advanced wound care market.

Portfolio Pulse from

November 20, 2024 | 12:15 pm

BioStem Technologies has signed a letter of intent to acquire wound care products and technologies from ProgenaCare Global, including ProgenaMatrix® and revyve™ Antimicrobial Wound Gel. This acquisition is part of BioStem's strategy to expand its commercial product portfolio.

Portfolio Pulse from

November 20, 2024 | 12:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.